| Literature DB >> 31767404 |
Efthimios Kyriakis1, Aikaterini G Karra1, Olga Papaioannou1, Theodora Solovou1, Vassiliki T Skamnaki1, Panagiota G V Liggri2, Spyros E Zographos3, Eszter Szennyes4, Éva Bokor4, Sándor Kun4, Anna-Maria G Psarra5, László Somsák6, Demetres D Leonidas7.
Abstract
C-Glucopyranosyl imidazoles, thiazoles, and an N-glucopyranosyl tetrazole were assessed in vitro and ex vivo for their inhibitory efficiency against isoforms of glycogen phosphorylase (GP; a validated pharmacological target for the development of anti-hyperglycaemic agents). Imidazoles proved to be more potent inhibitors than the corresponding thiazoles or the tetrazole. The most potent derivative has a 2-naphthyl substituent, a Ki value of 3.2 µM for hepatic glycogen phosphorylase, displaying also 60% inhibition of GP activity in HepG2 cells, compared to control vehicle treated cells, at 100 μM. X-Ray crystallography studies of the protein - inhibitor complexes revealed the importance of the architecture of inhibitor associated hydrogen bonds or sulfur σ-hole bond interactions to Asn284 OD1, offering new insights to structure-based design efforts. Moreover, while the 2-glucopyranosyl-tetrazole seems to bind differently from the corresponding 1,2,3-triazole compound, the two inhibitors are equipotent.Entities:
Year: 2019 PMID: 31767404 DOI: 10.1016/j.bmc.2019.115196
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641